Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases

Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases

US Patent 10640575 · Granted May 5, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Tissue-homing peptide conjugates and methods of use thereof2024
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and me2024
Methods of treating severe insulin resistance by interfering with glucagon recep2023
Tissue-homing peptide conjugates and methods of use thereof2023
Methods of treatment using IL-23p19 monoclonal antibodies2022
Cartilage-homing peptide conjugates and methods of use thereof2021
Methods of treating severe insulin resistance by interfering with glucagon recep2021
Treating inflammation with IL-17/IL-23 bispecific antibodies2020
Treating inflammation with IL-17/IL-23 bispecific antibodies2020
IL-23p19 monoclonal antibodies2019
Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodie2019
Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclon2018